Journal
VACCINE
Volume 27, Issue 52, Pages 7299-7303Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.08.023
Keywords
Memory B cells; Plasmodium falciparum; Malaria; Toll-like receptor 9
Categories
Funding
- National institute of Allergy and Infectious Diseases, National Institutes of Health
Ask authors/readers for more resources
Antibodies play a key role in controlling blood stage malaria infections, and an effective blood stage malaria vaccine will likely require that it induce vaccine-specific memory B cells (MBCs). Our previous studies showed that the addition of the TLR9 agonist CpG to Plasmodium falciparum protein subunit vaccines greatly increased their efficacy in inducing MBCs in nonimmune U.S. volunteers. Here we show that in contrast the same CpG-containing malaria vaccine did not enhance the acquisition of MBCs in semi-immune adults living in Mali. Understanding the molecular basis of this apparent refractoriness to TLR9 agonist will be of significant interest in vaccine design. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available